Results 241 to 250 of about 206,934 (330)

The fusion kinase ITK-SYK mimics a T cell receptor signal and drives oncogenesis in conditional mouse models of peripheral T cell lymphoma [PDF]

, 2010
Konstanze Pechloff, Julian Walter Holch, Uta Ferch, Marc Schweneker, Kristina Brunner, Markus Kremer, Tim Sparwasser, Leticia Quintanilla‐Martínez, Ursula Zimber‐Strobl, Berthold Streubel, Andreas Gewies, Christian Peschel, Jürgen Ruland   +12 more
openalex   +1 more source

Population Pharmacokinetic and Exposure‐Response Analyses of Ibrutinib Combined With Bendamustine and Rituximab in Patients With Mantle Cell Lymphoma

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Efficacy and safety of ibrutinib 560 mg once daily or placebo combined with bendamustine and rituximab (BR) were assessed in patients with mantle cell lymphoma in a randomized phase 3 study (SHINE). The analysis described explores the ibrutinib population pharmacokinetics (PK) and exposure‐response (E‐R) relationships of selected efficacy and ...
Per Olsson Gisleskog, Belén Valenzuela, Nicoline Treijtel, Sanjay Deshpande, Todd Henninger, Juan José Perez‐Ruixo   +5 more
wiley   +1 more source

Molecular heterogeneity of CD30⁺ peripheral T-cell lymphoma with prognostic significance and therapeutic implications: a retrospective multi-centre study. [PDF]

EBioMedicine
Huo YJ, Cheng S, Yi HM, Niu T, Fan L, Cui GH, Zhou FL, Song XM, Li F, Bai O, Yan XJ, Shi J, Cai MC, Huang YH, Dong L, Xiong J, Hu S, Qiu YR, Zhao Y, Xu PP, Wang L, Lu M, Jing HM, Zhao WL.   +23 more
europepmc   +1 more source

An Up‐to‐Date Review of Traditional Chinese Medicine in the Treatment of Atherosclerosis: Components, Mechanisms, and Therapeutic Potentials

Phytotherapy Research, EarlyView.
Traditional Chinese medicine in atherosclerosis: multi‐target modulation of pathogenesis. ABSTRACT Atherosclerosis is a chronic inflammatory disease and a major global health concern. In recent years, traditional Chinese medicines (TCMs) have demonstrated multi‐target therapeutic potential against atherosclerosis by modulating inflammatory responses ...
Dilaram Nijat, Qingzhe Zhao, Gulhasal Abdurixit, Jianhua He, Haipeng Liu, Jinyao Li   +5 more
wiley   +1 more source

Vanishing Bile Duct Syndrome Associated With Peripheral T Cell Lymphoma, Not Otherwise Specified, Arising in A Posttransplant Setting [PDF]

, 2010
Ryan M. Gill, Linda D. Ferrell
openalex   +1 more source

Multiple Successful Desensitizations to Brentuximab Vedotin in the Setting of Relapsed Peripheral T-Cell Lymphoma: Case Report. [PDF]

Can J Hosp Pharm
Rashid AR, Kuruvilla P.
europepmc   +1 more source

Impact of Autologous and Allogeneic Stem Cell Transplantation in Peripheral T-Cell Lymphomas [PDF]

, 2010
Peter Reimer
openalex   +1 more source

Nanoparticle Therapeutics in Clinical Perspective: Classification, Marketed Products, and Regulatory Landscape

Small, Volume 21, Issue 29, July 24, 2025.
This review presents a detailed overview of clinically approved nanoparticle therapeutics, classifying them by type and discussing their unique advantages in drug delivery. It highlights regulatory challenges across global markets and emphasizes the need for adaptive approval pathways.
Nimeet Desai, Dhwani Rana, Mitali Patel, Neha Bajwa, Rajendra Prasad, Lalitkumar K. Vora   +5 more
wiley   +1 more source

A multicenter, open-label, single-arm, phase Ib clinical trial of HH2853 treatment in patients with relapsed and/or refractory peripheral T-cell lymphoma. [PDF]

J Hematol Oncol
Hong H, Chen Z, Zhang M, Peng Z, Shen J, Shuang Y, Zhou H, Guo H, Huang H, Li F, Qian Z, Liu L, Wang L, Yang W, Zhang L, He P, Qian S, Li F, Li M, Lin T.   +19 more
europepmc   +1 more source

Comparison of four prognostic scores in peripheral T-cell lymphoma [PDF]

, 2010
Gonzalo Gutiérrez, Adriana García‐Herrera, Teresa Cardesa, Antonio Martı́nez, Neus Villamor, Gabriela Ghita, Alejandra Martínez‐Trillos, Luís Colomo, Xavier Setoaín, Sónia Rodríguez, Eva Giné, Elı́as Campo, Armando López‐Guillermo   +12 more
openalex   +1 more source